Xencor leads in the development of protein-based drugs. The company has an innovative protein engineering technology, a broad portfolio of differentiated antibodies, exceptional people, a reduced-risk strategy and validating partnerships. As patents expire and competition increases with biosimilars, Xencor is also well-positioned to support biopharmaceutical companies’ product differentiation, or the development of biosuperiors.
Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities and the solid intellectual property we have built around them. With XmAb®2513 through a Phase 1 clinical trial, XmAb®5574 (MOR208) moving into a Phase 1 trial, and a number of preclinical programs moving into development, we are at an exciting point in our growth as a biotechnology company.
Novo Nordisk Biotech Fund
Oxford Bioscience Partners
For more information, please contact us at firstname.lastname@example.org.